Home > Healthcare > Medical Devices > Diagnostic Devices > Breast Cancer Liquid Biopsy Market

Breast Cancer Liquid Biopsy Market Share

Report ID: GMI12188
Published Date: Nov 2024
Report Format: PDF

Download Free Sample

Breast Cancer Liquid Biopsy Market Share

The market is marked by intense competition among leading players who are concentrating on advancements in diagnostic technologies and innovative liquid biopsy solutions. Key companies are focused on innovation, investing heavily in research and development to enhance diagnostic accuracy and expand their product offerings. Strategic collaborations and partnerships are common, allowing firms to leverage complementary technologies and broaden market reach.

Additionally, rising awareness of non-invasive diagnostic techniques and supportive regulatory frameworks further intensify competition. Emerging players are also entering the market, contributing to a dynamic landscape that fosters advancements in liquid biopsy technologies. As the demand for early detection and personalized treatment options grows, maintaining a competitive edge through innovation and strategic positioning will be crucial for success.

Breast Cancer Liquid Biopsy Market Companies

Few of the prominent players operating in the breast cancer liquid biopsy industry include:

Datar Cancer Genetics
Epic Sciences
F. Hoffmann-La Roche
Genes2me
Illumina
Menarini Silicon Biosystems
Myriad Genetics
OncoDNA
QIAGEN
Sysmex
System Biosciences
Thermo Fisher Scientific
Twist Bioscience

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The global breast cancer liquid biopsy industry was valued at USD 305.9 million in 2023 and is estimated to grow at a 22.6% CAGR from 2024 to 2032, driven by the rising incidence of breast cancer and advancements in diagnostic technologies.

The cfDNA segment dominated the global market and is anticipated to grow at a 22.5% CAGR over the forecast period due to its non-invasive nature and ability to provide real-time insights into tumor dynamics.

U.S. breast cancer liquid biopsy industry accounted for USD 133.3 million in 2023 and is anticipated to grow significantly during the forecast period, supported by advanced healthcare infrastructure and substantial R&D investments.

Key players in the industry include Datar Cancer Genetics, Epic Sciences, F. Hoffmann-La Roche, Genes2me, Illumina, Menarini Silicon Biosystems, Myriad Genetics, OncoDNA, and QIAGEN.